Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006066 · ClinicalTrials.gov registry record · Phase 1
Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
- 14
- Study locations
NCT00006066: Completed Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00006066 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 92 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (79% lower). The trial reports 14 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006066, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to determine the safety of a drug called interleukin-2 (IL-2) given with anti-HIV therapy in children with HIV infection. This study will also determine the best dose of IL-2 to give children. IL-2 is an important substance produced by the body's white blood cells that helps the body fight infection. People with HIV infection do not produce enough IL-2. It is hoped that IL-2 treatment will help boost the immune system in people with HIV infection. It has not been studied very much in children and doctors need to know what doses are safe to give.
Conditions Studied
Interventions
- DRUG Aldesleukin
- BIOLOGICAL Tetanus and Diphtheria Toxoids Adsorbed
- BIOLOGICAL Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed
- BIOLOGICAL Diphtheria and Tetanus Toxoids Adsorbed
- DRUG Bacteriophage phi X 174
Study Locations (14)
California
- Long Beach Memorial Med. Ctr., Miller Children's Hosp. - Long Beach
- Usc La Nichd Crs - Los Angeles
- UCSD Maternal, Child, and Adolescent HIV CRS - San Diego
- UCSF Pediatric AIDS CRS - San Francisco
New York
- Nyu Ny Nichd Crs - New York
- Columbia IMPAACT CRS - New York
- SUNY Upstate Med. Univ., Dept. of Peds. - Syracuse
District of Columbia
- Children's National Med. Ctr. Washington DC NICHD CRS - Washington D.C.
- Children's National Med. Ctr., ACTU - Washington D.C.
Florida
- Univ. of Miami Ped. Perinatal HIV/AIDS CRS - Miami
- USF - Tampa NICHD CRS - Tampa
Louisiana
- Tulane/LSU Maternal/Child CRS - New Orleans
Massachusetts
- HMS - Children's Hosp. Boston, Div. of Infectious Diseases - Boston
Other
- Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Est. Completion | 2006-06 |
| Phase | Phase 1 |
What the finished NCT00006066 record still lists
NCT00006066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (79% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Aldesleukin is the first listed.
NCT00006066 lists 14 locations in 7 states (California, New York, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT00006066 about?
NCT00006066 is a clinical study titled "Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems". The purpose of this study is to determine the safety of a drug called interleukin-2 (IL-2) given with anti-HIV therapy in children with HIV infection. This study will also determine the best dose of IL-2 to give children. IL-2 is an important substance produced by the body's white blood cells that ...
What is the current status of trial NCT00006066?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. Estimated completion is 2006-06.
What conditions does trial NCT00006066 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00006066?
The interventions under investigation include: Aldesleukin (DRUG), Tetanus and Diphtheria Toxoids Adsorbed (BIOLOGICAL), Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed (BIOLOGICAL), Diphtheria and Tetanus Toxoids Adsorbed (BIOLOGICAL), Bacteriophage phi X 174 (DRUG).
Who is sponsoring clinical trial NCT00006066?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006066 being conducted?
This trial has 14 study locations across California, District of Columbia, Florida, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006066's enrollment target sits among peer trials
92 284th of 542 higher than 258 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma